Treatment of Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

August 7, 2020

Study Completion Date

January 5, 2021

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

botulinum toxin

neuromodulator to be injected in the GL region

BIOLOGICAL

Placebo

Placebo to be injected in the GL area

Trial Locations (14)

10021

Robert Schwarcz, MD, PC, New York

Sachin M Shridharani, MD, New York

21030

Maryland Dermatology, Laser Skin & Vein, Hunt Valley

28405

Wilmington Dermatology Center, PLLC, Wilmington

37203

The Practice of Brian S Biesman, MD, Nashville

37215

Tennessee Clinical Research Center, Nashville

68144

Skin Specialist, PC, Omaha

70130

Etre Cosmetic Dermatology and Laser Center, New Orleans

75225

Dallas Center for Dermatology & Aesthetics, Dallas

77388

Integrated Aesthetics, Inc, Spring

78660

Austin Institute for Clinical Research, Inc., Pflugerville

90266

\Ablon Skin Institute and Research Center, Manhattan Beach

92083

Moradi MD, Vista

M5R 3N8

Sweat Clinics of Canada, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY